Beyond Prostate-specific Antigen: Utilizing Novel Strategies to Screen Men for Prostate Cancer

Overview

Journal Curr Opin Urol

Specialty Urology

Date 2016 Jun 5

PMID 27262138

Citations 21

Authors

Stacy Loeb

Hans Lilja

Andrew Vickers

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: The purpose of this article is to review blood and urine tests that are currently available and under investigation for a role in prostate cancer screening and detection.

Recent Findings: Compared with total prostate-specific antigen (PSA) alone, its combination with percentage free-to-total PSA contributes greater specificity for prostate cancer, and is a component of two newer blood tests called the 4kScore and Prostate Health Index. All three tests improve the prediction of high-grade disease and are commercially available options to aid in initial or repeat prostate biopsy decisions. PCA3 is a urinary marker that is currently available for repeat prostate biopsy decisions. Although PCA3 alone has inferior prediction of clinically significant disease and requires collection of urine after digital rectal examination, it may be combined with other clinical variables or other urine markers like TMPRSS2:ERG to improve performance. Little data are available to support a role for single nucleotide polymorphisms or other investigational markers in early detection.

Summary: Several commercially available blood and urine tests have been shown to improve specificity of PSA for high-grade prostate cancer. Use of such tests would decrease unnecessary biopsy and overdiagnosis of indolent disease. Biopsy of men with moderately elevated PSA without use of such a reflex test should be discouraged.

Citing Articles

Effect of prostate volume on the predictive value of prostate-specific antigen density for prostate cancer.

Liu Z, Yu Y, Hu R, Jian T, Yu K, Lu J Transl Androl Urol. 2025; 14(1):70-80.

PMID: 39974811 PMC: 11833531. DOI: 10.21037/tau-24-490.

Phage Display's Prospects for Early Diagnosis of Prostate Cancer.

Petrenko V Viruses. 2024; 16(2).

PMID: 38400052 PMC: 10892688. DOI: 10.3390/v16020277.

Economic evaluation of prostate cancer risk assessment methods: A cost-effectiveness analysis using population data.

Mohammadi T, Guh D, Tam A, Pataky R, Black P, So A Cancer Med. 2023; 12(19):20106-20118.

PMID: 37740609 PMC: 10587968. DOI: 10.1002/cam4.6587.

Prostate cancer screening in African American men: a review of the evidence.

Kensler K, Johnson R, Morley F, Albrair M, Dickerman B, Gulati R J Natl Cancer Inst. 2023; 116(1):34-52.

PMID: 37713266 PMC: 10777677. DOI: 10.1093/jnci/djad193.

The roles of proteases in prostate cancer.

Koistinen H, Kovanen R, Hollenberg M, Dufour A, Radisky E, Stenman U IUBMB Life. 2023; 75(6):493-513.

PMID: 36598826 PMC: 10159896. DOI: 10.1002/iub.2700.

References

Bussemakers M, van Bokhoven A, Verhaegh G, Smit F, Karthaus H, Schalken J . DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res. 1999; 59(23):5975-9. View

Gronberg H, Adolfsson J, Aly M, Nordstrom T, Wiklund P, Brandberg Y . Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study. Lancet Oncol. 2015; 16(16):1667-76. DOI: 10.1016/S1470-2045(15)00361-7. View

Pandha H, Sorensen K, Orntoft T, Langley S, Hoyer S, Borre M . Urinary engrailed-2 (EN2) levels predict tumour volume in men undergoing radical prostatectomy for prostate cancer. BJU Int. 2012; 110(6 Pt B):E287-92. DOI: 10.1111/j.1464-410X.2012.11208.x. View

Guazzoni G, Lazzeri M, Nava L, Lughezzani G, Larcher A, Scattoni V . Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer. Eur Urol. 2011; 61(3):455-66. DOI: 10.1016/j.eururo.2011.10.038. View

Kadimisetty K, Mosa I, Malla S, Satterwhite-Warden J, Kuhns T, Faria R . 3D-printed supercapacitor-powered electrochemiluminescent protein immunoarray. Biosens Bioelectron. 2015; 77:188-93. PMC: 4673015. DOI: 10.1016/j.bios.2015.09.017. View

Loeb S, Sanda M, Broyles D, Shin S, Bangma C, Wei J . The prostate health index selectively identifies clinically significant prostate cancer. J Urol. 2014; 193(4):1163-9. PMC: 4404198. DOI: 10.1016/j.juro.2014.10.121. View

Alahari S, Eastlack S, Alahari S . Role of Long Noncoding RNAs in Neoplasia: Special Emphasis on Prostate Cancer. Int Rev Cell Mol Biol. 2016; 324:229-54. DOI: 10.1016/bs.ircmb.2016.01.004. View

Bertoli G, Cava C, Castiglioni I . MicroRNAs as Biomarkers for Diagnosis, Prognosis and Theranostics in Prostate Cancer. Int J Mol Sci. 2016; 17(3):421. PMC: 4813272. DOI: 10.3390/ijms17030421. View

Park J, Wacholder S, Gail M, Peters U, Jacobs K, Chanock S . Estimation of effect size distribution from genome-wide association studies and implications for future discoveries. Nat Genet. 2010; 42(7):570-5. PMC: 4615599. DOI: 10.1038/ng.610. View

10.

Lughezzani G, Lazzeri M, Haese A, McNicholas T, De La Taille A, Buffi N . Multicenter European external validation of a prostate health index-based nomogram for predicting prostate cancer at extended biopsy. Eur Urol. 2013; 66(5):906-12. DOI: 10.1016/j.eururo.2013.12.005. View

11.

de la Calle C, Patil D, Wei J, Scherr D, Sokoll L, Chan D . Multicenter Evaluation of the Prostate Health Index to Detect Aggressive Prostate Cancer in Biopsy Naïve Men. J Urol. 2015; 194(1):65-72. PMC: 4696043. DOI: 10.1016/j.juro.2015.01.091. View

12.

Vickers A, Cronin A, Aus G, Pihl C, Becker C, Pettersson K . Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate-specific antigen: data from the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden. Cancer. 2010; 116(11):2612-20. PMC: 2882167. DOI: 10.1002/cncr.25010. View

13.

McKiernan J, Donovan M, ONeill V, Bentink S, Noerholm M, Belzer S . A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy. JAMA Oncol. 2016; 2(7):882-9. DOI: 10.1001/jamaoncol.2016.0097. View

14.

Klein R, Hallden C, Gupta A, Savage C, Dahlin A, Bjartell A . Evaluation of multiple risk-associated single nucleotide polymorphisms versus prostate-specific antigen at baseline to predict prostate cancer in unscreened men. Eur Urol. 2011; 61(3):471-7. PMC: 3269546. DOI: 10.1016/j.eururo.2011.10.047. View

15.

Wang X, Yu J, Sreekumar A, Varambally S, Shen R, Giacherio D . Autoantibody signatures in prostate cancer. N Engl J Med. 2005; 353(12):1224-35. DOI: 10.1056/NEJMoa051931. View

16.

Liss M, Santos R, Osann K, Lau A, Ahlering T, Ornstein D . PCA3 molecular urine assay for prostate cancer: association with pathologic features and impact of collection protocols. World J Urol. 2010; 29(5):683-8. PMC: 3189407. DOI: 10.1007/s00345-010-0623-6. View

17.

Sreekumar A, Poisson L, Rajendiran T, Khan A, Cao Q, Yu J . Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 2009; 457(7231):910-4. PMC: 2724746. DOI: 10.1038/nature07762. View

18.

Wei J, Feng Z, Partin A, Brown E, Thompson I, Sokoll L . Can urinary PCA3 supplement PSA in the early detection of prostate cancer?. J Clin Oncol. 2014; 32(36):4066-72. PMC: 4265117. DOI: 10.1200/JCO.2013.52.8505. View

19.

Gao R, Cheng Z, deMello A, Choo J . Wash-free magnetic immunoassay of the PSA cancer marker using SERS and droplet microfluidics. Lab Chip. 2016; 16(6):1022-9. DOI: 10.1039/c5lc01249j. View

20.

Haese A, De La Taille A, van Poppel H, Marberger M, Stenzl A, Mulders P . Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol. 2008; 54(5):1081-8. DOI: 10.1016/j.eururo.2008.06.071. View